SEC suggests approval for remdesivir in tablet form

Remdesivir, an antiviral used for treatment of Covid-19, may soon be available in tablet form as a top panel of the country’s drug regulator has recommended its emergency use authorisation (EUA), people in the know told ET.

The Subject Expert Committee (SEC) of Central Drugs Standards Control Organisation (CDSCO) in a meeting on Friday recommended EUA for remdesivir tablets proposed by Jubilant Life Sciences, they said.

“The drug regulator will soon take a decision regarding the same,” a government official said.


Remdesivir is currently administered in the country through intravenous route.

Jubilant is planning to launch 20 mg sub-lingual tablets of remdesivir, sources said.

Sub-lingual administration involves placing a drug under the tongue so that it gets dissolved and absorbed into the blood through the tissues.

An email sent to Jubilant Life Sciences did not elicit any response till press time Tuesday.